- €941.31m
- €913.90m
- €19.52m
Brief: Medincell SA - Receives $3 Million Grant From Gates Foundation To Fight Malaria
Medincell at fresh record high FDA expands indication for schizophrenia treatment
Brief: MedinCell: FDA Approves Expanded Indication For Uzedy
French and Benelux stocks-Factors to watch
Brief: Teva And Medincell’S Risperidone Lai Approved In Canada As Longavo®
Teva Pharma rises after positive late-stage trial data for schizophrenia drug
Brief: Medincell Data Shows Uzedy Leads To Faster Discharge
Brief: Medincell Says Phase 3 Data Shows No PDSS In Olanzapine LAI
Medincell hits 5-year high after South Korea approves co's schizophrenia treatment
French and Benelux stocks-Factors to watch
Brief: Medincell FY Revenue EUR 25.4 MLN
Brief: Medincell Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
Bureau Veritas to replace Vivendi on CAC40 index, Euronext says
French and Benelux stocks-Factors to watch
Brief: Medincell H1 Operating Profit Up At EUR -7.5 Mln
Brief: Medincell, AIC Unveil New Positive Phase 3 Results For Mdc-CWM
Brief: Medincell Raises 2024 Uzedy Revenue Outlook To $100 Million
Brief: Medincell's Partner Teva Presents Data From Phase 3 Of Olanzapine Lai
Brief: Medincell-Teva Updates On Pivotal Clinical Phase 3 Of Investigational Olanzapine LAI